AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|
27.9 C
New York
Tuesday, September 1, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

UTGL Donates HK$650,000 to Advance Anti-Aging, Cardiovascular Health and Healthy Longevity Through Corporate Social Responsibility and Clinical Research

HONG KONG, June 5, 2026 /PRNewswire/ -- UniTrust Global Limited | UTGL announced a donation of HK$650,000 to Prime Healthcare Medical Services Limited in...

Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels 
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

Herbalgy “TO-Go” Summer Treat: Keung To-Themed Gelato Truck

Free Gelato + Exclusive Fan Support Hand Fan, Stay Cool. Stay "TO". One Receipt, Triple Summer Rewards: Win The Herbalgy Trophy Tickets!HONG KONG, June 5, 2026...

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital 
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital

London Specialist Dentists Announce the Use of Ozone Therapy in Periodontal Treatment and Dental Implants

LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.

Seven Arrows Recovery Expands Public Education Efforts Around Forward-Facing, Nervous System Centred Addiction Treatment

The Arizona residential treatment center introduces broader awareness of its trauma-informed and salutogenic recovery model through Forward-Facing® Accelerated Recovery 
The Arizona residential treatment center introduces broader awareness of its trauma-informed and salutogenic recovery model through Forward-Facing® Accelerated Recovery

TAMPA MUSEUM OF ART CELEBRATES MAUREEN AND DOUG COHN WITH NAMING OF CONTEMPORARY ART GALLERY

TAMPA, Fla., June 4, 2026 /PRNewswire/ -- The Tampa Museum of Art today announced a transformative gift from longtime Museum leaders and supporters Maureen...

Massage Envy Celebrates 20 Million Skin Care Services Milestone

Achievement highlights more than 17 years of growth in personalized, accessible, and results-driven skin careSCOTTSDALE, Ariz., June 4, 2026 /PRNewswire/ -- Massage Envy, a national...

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

June 4, 2026

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers